CCL

Összesen 8 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM062336
Első szerző:Fontebasso, Adam M.
Cím:Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age / Adam M. Fontebasso, Margret Shirinian, Dong-Anh Khuong-Quang, Denise Bechet, Tenzin Gayden, Marcel Kool, Nicolas De Jay, Karine Jacob, Noha Gerges, Barbara Hutter, Huriye Şeker-Cin, Hendrik Witt, Alexandre Montpetit, Sébastien Brunet, Pierre Lepage, Geneviève Bourret, Almos Klekner, László Bognár, Peter Hauser, Miklós Garami, Jean-Pierre Farmer, Jose-Luis Montes, Jeffrey Atkinson, Sally Lambert, Tony Kwan, Andrey Korshunov, Uri Tabori, V. Peter Collins, Steffen Albrecht, Damien Faury, Stefan M. Pfister, Werner Paulus, Martin Hasselblatt, David T. W. Jones, Nada Jabado
Dátum:2015
ISSN:1949-2553
Megjegyzések:Pilocytic astrocytoma (PA) is the most common brain tumor in children but israre in adults, and hence poorly studied in this age group. We investigated 222 PA andreport increased aneuploidy in older patients. Aneuploid genomes were identified in45% of adult compared with 17% of pediatric PA. Gains were non-random, favoringchromosomes 5, 7, 6 and 11 in order of frequency, and preferentially affecting noncerebellarPA and tumors with BRAF V600E mutations and not with KIAA1549-BRAFfusions or FGFR1 mutations. Aneuploid PA differentially expressed genes involved inCNS development, the unfolded protein response, and regulators of genomic stabilityand the cell cycle (MDM2, PLK2), whose correlated programs were overexpressedspecifically in aneuploid PA compared to other glial tumors. Thus, convergence of pathways affecting the cell cycle and genomic stability may favor aneuploidy in PA, possiblyrepresenting an additional molecular driver in older patients with this brain tumor.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
pilocytic astrocytoma
aneuploidy
BRAF
MDM2
PLK2
Megjelenés:Oncotarget. - 6 : 31 (2015), p. 31844-31856. -
További szerzők:Shirinian, Margret Khuong-Quang, Dong-Anh Bechet, Denise Gayden, Tenzin Kool, Marcel De Jay, Nicolas Jacob, Karine Gerges, Noha Hutter, Barbara Şeker-Cin, Huriye Witt, Hendrik Montpetit, Alexandre Brunet, Sébastien Lepage, Pierre Bourret, Geneviève Klekner Álmos (1970-) (idegsebész) Bognár László (1958-) (idegsebész, gyermekidegsebész) Hauser Péter Garami Miklós Farmer, Jean-Pierre Montes, Jose-Luis Atkinson, Jeffrey Lambert, Sally Kwan, Tony Korshunov, Andrey Tabori, Uri Collins, V. Peter Albrecht, Stephen Faury, Damien Pfister, Stefan M. Paulus, Werner Hasselblatt, Martin Jones, David T. W. Jabado, Nada
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM068318
Első szerző:Klement, Giannoula Lakka
Cím:Future paradigms for precision oncology / Giannoula Lakka Klement, Knarik Arkun, Dalibor Valik, Tina Roffidal, Ali Hashemi, Christos Klement, Paolo Carmassi, Edward Rietman, Ondrej Slaby, Pavel Mazanek, Peter Mudry, Gabor Kovacs, Csongor Kiss, Koen Norga, Dobrin Konstantinov, Nicolas André, Irene Slavc, Henk van Den Berg, Alexandra Kolenova, Leos Kren, Jiri Tuma, Jarmila Skotakova, Jaroslav Sterba
Dátum:2016
ISSN:1949-2553
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
tumor
paradigm
Megjelenés:Oncotarget. - 7 : 29 (2016), p. 46813-46831. -
További szerzők:Arkun, Knarik Valik, Dalibor Roffidal, Tina Hashemi, Ali Klement, Christos Carmassi, Paolo Rietman, Edward Slaby, Ondrej Mazanek, Pavel Mudry, Peter Kovács Gábor (gyermekhaematológus Budapest) Kiss Csongor (1956-) (hematológus, onkológus) Norga, Koen Konstantinov, Dobrin André, Nicolas Slavc, Irene van Den Berg, Henk Kolenova, Alexandra Kren, Leos Tuma, Jiri Skotakova, Jarmila Sterba, Jaroslav
Pályázati támogatás:OTKA-108885
OTKA
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM083143
Első szerző:Molnár-Fodor Klára (biotechnológus)
Cím:The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma / Klara Fodor, Nikoletta Dobos, Andrew Schally, Zita Steiber, Gabor Olah, Eva Sipos, Lorant Szekvolgyi, Gabor Halmos
Dátum:2020
ISSN:1949-2553 1949-2553
Megjegyzések:Uveal melanoma (UM) is the most common malignant tumor of the eye. Recently, we have established that 46% of UM specimens express LHRH receptors. This finding supports the idea of a LHRH receptor-targeted therapy of UM patients. Cytotoxic analog of LHRH, AEZS-108 exhibits effective anti-cancer activity in LHRH-receptor positive cancers. AEZS-108 is a hybrid molecule, composed of a synthetic peptide carrier and the cytotoxic doxorubicin (DOX). In the present study, we investigated AEZS-108 induced cytotoxicity and the altered mRNA expression profile of regulatory factors related to angiogenesis and metastasis in LHRH receptor positive OCM3 cells. Our results show that AEZS-108 upregulates the expression of MASPIN/SERPINB5 tumor suppressor gene, which is downregulated in normal uvea and UM specimens independently from the LHRH receptor-ligand interaction. AEZS-108 also substantially downregulates hypoxia-inducible factor 1 alpha (HIF1A) expression. In order to investigate the mechanism of the induction of MASPIN by AEZS-108, OCM3 cells were treated with free DOX, D-Lys6 LHRH analog, or AEZS-108. qRT- PCR analysis revealed in OCM3 cells that AEZS-108 is a more potent inducer of MASPIN than free DOX. In conclusion, we show for the first time that AEZS-108 has a major impact in the regulation of angiogenesis thus plays a potential role in tumor suppression. Taken together, our results support the development of novel therapeutic strategies for UM focusing on LHRH receptors.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
uveal melanoma
luteinizing hormone-releasing hormone (LHRH) receptor
angiogenesis
MASPIN/SERPINB5
AEZS-108 (AN-152/Zoptarelin Doxorubicin Acetate)
Megjelenés:Oncotarget. - 11 : 2 (2020), p. 175-187. -
További szerzők:Dobos Nikoletta (1981-) (biológus) Schally, Andrew Victor Steiber Zita (1977-) (orvos, szemész) Oláh Gábor (1987-) (gyógyszerész) Sipos Éva (1989-) (gyógyszerész) Székvölgyi Lóránt (1977-) (biofizikus, biokémikus, sejtbiológus) Halmos Gábor (1962-) (gyógyszerész, receptorfarmakológus, experimentális onkológus)
Pályázati támogatás:GINOP-2.3.2-15-2016-00024
GINOP
MTA-DE Lendület
MTA
Élettudományok - Orvosi tudományok
OTKA-K 81596
OTKA
TÁMOP-4.2.2.A-11/1/KONV-2012-0025
TÁMOP
GINOP-2.3.2-15-2016-00043
GINOP
GINOP-2.3.2-15-2016-00024
GINOP
TÁMOP-4.2.4.A/2-11-1-2012-0001
TÁMOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM068928
Első szerző:Murnyák Balázs (molekuláris biológus, genetikus)
Cím:PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma / Balázs Murnyák, Mahan C. Kouhsari, Rotem Hershkovitch, Bernadette Kálmán, György Marko-Varga, Álmos Klekner, Tibor Hortobágyi
Dátum:2017
ISSN:1949-2553
Megjegyzések:Overexpression of PARP1 exists in various cancers, including glioblastoma (GBM). Although PARP1 inhibition is a promising therapeutic target, no comprehensive study has addressed PARP1's expression characteristics and prognostic role regarding molecular heterogeneity in astrocytomas including GBM. Our aim was to evaluate PARP1's associations with survival, WHO grade, lineage specific markers, and GBM transcriptomic subtypes. We collected genomic and clinical data from the latest glioma datasets of The Cancer Genome Atlas and performed PARP1, ATRX, IDH1, and p53 immunohistochemistry on GBM tissue samples. We demonstrated that PARP1 gain and increased mRNA expression are characteristics of high-grade astrocytomas, particularly of Proneural and Classical GBM subtypes. Additionally, higher PARP1 levels exhibited an inverse correlation with patient survival (p<0.005) in the Classical subgroup. ATRX (p=0.006), and TP53 (p=0.015) mutations were associated with increased PARP1 expression and PARP1 protein level correlated with ATRX loss and p53 overexpression. Furthermore, higher PARP1 expression together with wildtype TP53 indicated shorter survival (p=0.039). Therefore, due to subtype specificity, PARP1 expression level and TP53 mutation status are reliable marker candidates to distinguish Proneural and Classical subtypes, with prognostic and therapeutic implications in GBM.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
glioma
glioblastoma
p53
PARP1
Megjelenés:Oncotarget. - 8 : 28 (2017), p. 46348-46362. -
További szerzők:Kouhsari, Mahan C. Hershkovitch, Rotem Kálmán Bernadette Marko-Varga György Klekner Álmos (1970-) (idegsebész) Hortobágyi Tibor (1965-) (patológus)
Pályázati támogatás:ÚNKP-16-3
Egyéb
KTIA_13_NAP-A-II/7
Egyéb
KTIA_13_NAP-A-V/3
Egyéb
AGR_PIAC_13-1-2013-0008
Egyéb
GINOP-2.3.2-15-2016-00043
GINOP
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

5.

001-es BibID:BIBFORM065513
Első szerző:Murnyák Balázs (molekuláris biológus, genetikus)
Cím:Immunohistochemical correlates of TP53 somatic mutations in cancer / Balázs Murnyák, Tibor Hortobágyi
Dátum:2016
ISSN:1949-2553
Megjegyzések:Despite controversy on the correlation between p53 accumulation and TP53 mutational status, immunohistochemical (IHC) detection of overexpressed protein has long been used as a surrogate method for mutation analysis. The aim of our study was to characterise the IHC expression features of TP53 somatic mutations and define their occurrence in human cancers. A large-scale database analysis was conducted in the IARC TP53 Database (R17); 7878 mutations with IHC features were retrieved representing 60 distinct tumour sites. The majority of the alterations were immunopositive (p<0.001). Sex was known for 4897 mutations showing a female dominance (57.2%) and females carrying negative mutations were significantly younger. TP53 mutations were divided into three IHC groups according to mutation frequency and IHC positivity. Each group had female dominance. Among the IHC groups, significant correlations were observed with age at diagnosis in breast, bladder, liver, haematopoietic system and head & neck cancers. An increased likelihood of false negative IHC associated with rare nonsense mutations was observed in certain tumour sites. Our study demonstrates that p53 immunopositivity largely correlates with TP53 mutational status but that expression is absent in certain mutation types. Besides, describing the complex IHC expression of TP53 somatic mutations, our results reveal some caveats for the diagnostic practice.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
IARC TP53 Database
Immunohistochemistry
TP53 mutations
cancer
p53
Megjelenés:Oncotarget 7 : 40 (2016), p. 64910-64920. -
További szerzők:Hortobágyi Tibor (1965-) (patológus)
Pályázati támogatás:KTIA_13_NAP-A-II/7
Egyéb
KTIA_13_NAP-A-V/3
Egyéb
AGR_PIAC_13-1-2013-0008
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM074593
Első szerző:Ozgyin Lilla (molekuláris biológus)
Cím:Lyophilized human cells stored at room temperature preserve multiple RNA species at excellent quality for RNA sequencing / Ozgyin Lilla, Horvath Attila, Balint Balint Laszlo
Dátum:2018
ISSN:1949-2553
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
liofilizálás
fagyasztva-szárítás
RNS
Megjelenés:Oncotarget. - 9 : 59 (2018), p. 31312-31329. -
További szerzők:Horváth Attila (1988-) (programtervező informatikus) Bálint Bálint László (1971-) (kutató orvos)
Pályázati támogatás:TAMOP 4.2.4.A/2-11-1-2012-0001
TÁMOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM071707
Első szerző:Szujó Szabina
Cím:The impact of post-radioiodine therapy SPECT/CT on early risk stratification in differentiated thyroid cancer : a bi-institutional study / Szujo Szabina, Sira Livia, Bajnok Laszlo, Bodis Beata, Gyory Ferenc, Nemes Orsolya, Rucz Karoly, Kenyeres Peter, Valkusz Zsuzsanna, Sepp Krisztian, Schmidt Erzsebet, Szabo Zsuszanna, Szekeres Sarolta, Zambo Katalin, Barna Sandor, Nagy Endre V., Mezosi, Emese
Dátum:2017
ISSN:1949-2553
Megjegyzések:Objective: SPECT/CT has numerous advantages over planar and traditional SPECT images. The aim of this study was to evaluate the role of post-radioiodine therapy SPECT/CT of patients with differentiated thyroid cancer (DTC) in early risk classification and in prediction of late prognosis.Patients and methods: 323 consecutive patients were investigated after their first radioiodine treatment (1100?3700 MBq). Both whole body scan and SPECT/CT images of the head, neck, chest and abdomen regions were taken 4?6 days after radioiodine therapy. Patients were re-evaluated 9?12 months later as well as at the end of follow up (median 37 months).Results: Post-radioiodine therapy SPECT/CT showed metastases in 22% of patients. Lymph node, lung and bone metastases were detected in 61, 13 and 5 patients, respectively, resulting in early reclassification of 115 cases (36%). Noevidence of disease was found in 251 cases at 9?12 months after radioiodine treatment and 269 patients at the end of follow-up. To predict residual disease at the end offollow-up, the sensitivities, specificities and diagnostic accuracies of the current risk classification systems and SPECT/CT were: ATA: 77%, 47% and 53%; ETA: 70%,62% and 64%; SPECT/CT: 61%, 88% and 83%, respectively. There was no difference between cohorts of the two institutions when data were analyzed separately.Conclusions: Based on our bi-institutional experience, the accuracy of postradioiodine SPECT/CT outweighs that of the currently used ATA and ETA risk classification systems in the prediction of long-term outcome of DTC.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
differentiated thyroid cancer
radioiodine therapy
SPECT/CT
ATA risk classification
ETA risk classification
Megjelenés:Oncotarget. - 8 : 45 (2017), p. 79825-79834. -
További szerzők:Sira Lívia (1973-) (endokrinológus) Bajnok László (1961-) (belgyógyász) Bódis Beáta Győry Ferenc (1969-) (kardiológus) Nemes Orsolya Rucz Károly Kenyeres Péter Valkusz Zsuzsanna Sepp Krisztián Schmidt Erzsébet Szabó Zsuszanna (Pécs) Szekeres Sarolta Zámbó Katalin Barna Sándor (1982-) (kutató orvos) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Mezősi Emese
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM048907
035-os BibID:(PMID)24077773
Első szerző:Treszl Andrea (molekuláris biológus)
Cím:Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma / Andrea Treszl, Zita Steiber, Andrew V. Schally, Norman L. Block, Balazs Dezso, Gabor Olah, Bernadett Rozsa, Klara Fodor, Armin Buglyo, Janos Gardi, Andras Berta, Gabor Halmos
Dátum:2013
ISSN:1949-2553
Megjegyzések:Uveal melanoma is the most common primary intraocular malignancy in adults, with a very high mortality rate due to frequent liver metastases. Consequently, the therapy of uveal melanoma remains a major clinical challenge and new treatment approaches are needed. For improving diagnosis and designing a rational and effective therapy, it is essential to elucidate molecular characteristics of this malignancy. The aim of this study therefore was to evaluate as a potential therapeutic target the expression of luteinizing hormone-releasing hormone (LHRH) receptor in human uveal melanoma. The expression of LHRH ligand and LHRH receptor transcript forms was studied in 39 human uveal melanoma specimens by RT-PCR using gene specific primers. The binding charachteristics of receptors for LHRH on 10 samples were determined by ligand competition assays. The presence of LHRH receptor protein was further evaluated by immunohistochemistry. The expression of mRNA for type I LHRH receptor was detected in 18 of 39 (46%) of tissue specimens. mRNA for LHRH-I ligand could be detected in 27 of 39 (69%) of the samples. Seven of 10 samples investigated showed high affinity LHRH-I receptors. The specific presence of full length LHRH receptor protein was further confirmed by immunohistochemistry. A high percentage of uveal melanomas express mRNA and protein for type-I LHRH receptors. Our results support the merit of further investigation of LHRH receptors in human ophthalmological tumors. Since diverse analogs of LHRH are in clinical trials or are already used for the treatment of various cancers, theseanalogs could be considered for the LHRH receptor-based treatment of uveal melanoma.
Tárgyszavak:Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
uveal melanoma
luteinizing hormone-releasing hormone (LHRH) receptor
Megjelenés:Oncotarget. - 4 : 10 (2013), p. 1721-1728. -
További szerzők:Steiber Zita (1977-) (orvos, szemész) Schally, Andrew Victor Block, Norman L. Dezső Balázs (1951-) (pathológus) Oláh Gábor (1987-) (gyógyszerész) Rózsa Bernadett (1981-) (molekuláris biológus) Molnár-Fodor Klára (1989-) (biotechnológus) Buglyó Armin Gardi János Berta András (1955-) (szemész, gyermekszemész) Halmos Gábor (1962-) (gyógyszerész, receptorfarmakológus, experimentális onkológus)
Pályázati támogatás:TÁMOP-4.2.2.A-11/1/KONV-2012-0025
TÁMOP
K81596
OTKA
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.